At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 200 target
Drug / intervention
PD1/PDL1/CTLA4 inhibitorsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II/III Randomized Trial of Comparison of Survival Benefit of Administration of PD1/PDL1/CTLA4 Inhibitors or Their Combinations Via Neck Artery or Intratumor Versus Vein Infusion for Immunotherapy of HNC
Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted May 16, 2019·Updated Jun 26, 2024
In Brief
A Phase 3 clinical trial evaluating PD1/PDL1/CTLA4 inhibitors for Head/Neck Neoplasm. Currently recruiting, targeting 200 participants across 1 site.
Detailed Summary
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with advanced Head/Neck Squamous cancer via intra-tumor or intra-artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead/Neck Neoplasm
CountriesChina
Collaborators--
Timeline
Phase 3Recruiting
20192020202120222023202420252026202720282029203020312032203320342035
Enrollment StartJan 2019
First PostedMay 2019
TodayJul 2026
Primary CompletionJan 2029
Study CompletionJan 2035
First PostedMay 16, 2019
Enrollment StartJan 1, 2019
Primary CompletionJan 1, 2029
Study CompletionJan 1, 2035
TodayJul 1, 2026
Enrollment to primary: 10 yearsPosted 7.1 years agoPrimary completion in 2.5 years
Interventions
PD1/PDL1/CTLA4 inhibitorsdrug
Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.